1. Yang J, Zheng Y, Gou X, et al. 2020; Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 94:91–95. DOI:
10.1016/j.ijid.2020.03.017. PMID:
32173574. PMCID:
PMC7194638.
Article
4. Albillos A, Lario M, Álvarez-Mon M. 2014; Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 61:1385–1396. DOI:
10.1016/j.jhep.2014.08.010. PMID:
25135860.
Article
5. Mao R, Qiu Y, He JS, et al. 2020; Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 5:667–678. DOI:
10.1016/S2468-1253(20)30126-6.
Article
7. Fix OK, Hameed B, Fontana RJ, et al. 2020; Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 72:287–304. DOI:
10.1002/hep.31281. PMID:
32298473. PMCID:
PMC7262242.
Article
8. Mahmud N, Hubbard RA, Kaplan DE, Serper M. 2020; Declining cirrhosis hospitalizations in the wake of the COVID-19 pandemic: a national cohort study. Gastroenterology. 159:1134–1136.e3. DOI:
10.1053/j.gastro.2020.05.005. PMID:
32387493. PMCID:
PMC7200325.
Article
10. Cho JY, Kim SS, Lee YS, Song DS, Lee JH, Kim JH. 2020; Management of liver diseases during the pandemic of coronavirus disease-19. Clin Mol Hepatol. 26:243–250. DOI:
10.3350/cmh.2020.0111. PMID:
32570302. PMCID:
PMC7364349.
Article
14. Kim D, Adeniji N, Latt N, et al. 2020; Sep. 17. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol. [Epub ahead of print]. DOI:
10.1016/j.cgh.2020.09.027.
Article
15. Bajaj JS, Garcia-Tsao G, Biggins SW, et al. 2021; Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 70:531–536. DOI:
10.1136/gutjnl-2020-322118. PMID:
32660964. PMCID:
PMC7371484.
Article
16. Lee YR, Kang MK, Song JE, et al. 2020; Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: a multicenter study in South Korea. Clin Mol Hepatol. 26:562–576. DOI:
10.3350/cmh.2020.0126. PMID:
33053932. PMCID:
PMC7641571.
Article
17. Qi X, Liu Y, Wang J, et al. 2021; Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 70:433–436. DOI:
10.1136/gutjnl-2020-321666. PMID:
32434831. PMCID:
PMC7815629.
Article
18. Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. 2020; Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 5:643–644. DOI:
10.1016/S2468-1253(20)30125-4.
Article
19. Wang Y, Zhang D, Du G, et al. 2020; Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 395:1569–1578. DOI:
10.1016/S0140-6736(20)31022-9.